NVIDIA

Powering Healthcare AI Innovation

Ho Chi Minh, California, Vietnam

NVIDIA is a publicly traded technology company on NASDAQ (NVDA) that is a major investor in AI and deep learning. It has made significant investments in companies like OpenAI, Anthropic, Mistral AI, and Cohere, and partners with GE HealthCare for medical technology development.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out NVIDIA on @MedStartr Today NVIDIA is a publicly traded technology company on NASDAQ (NVDA) that is a major investor in AI and deep learning. It has made significant investments in companies like OpenAI, Anthropic, Mistral AI, and Cohere, and partners with GE HealthCare for medical technology development. #ImmunologyAndInfectiousDiseases #RespiratoryDiseases #NeurodegenerativeDiseases #RareDiseases #CardiovascularDisease #CentralNervousSystemDisorders #CancerOncology #Other #AIML #AIHardware #MedMo #MedStartrVentures

https://www.medstartr.ai/s/yPjLacA4MOM

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in NVIDIA

How We Help

Problem Statement

Healthcare stakeholders often lack the foundational computing power and advanced AI tools necessary to drive innovation efficiently. NVIDIA solves this by providing essential hardware and software infrastructure, reducing barriers to entry for developing new diagnostics, therapies, and operational efficiencies.

Core Technology

Graphics Processing Units (GPUs), Artificial Intelligence (AI) and Deep Learning, Accelerated Computing, Specialized Platforms (NVIDIA Clara, BioNeMo, Holoscan, MONAI, Isaac for Healthcare), Digital Twin Technology

Key Differentiators

GPU Leadership, Full-Stack AI Platform, Ecosystem Enablement, Pioneering AI in Physical World (Physical AI), Accelerated Drug Discovery and Genomics, Strategic Partnerships (with nearly 200 organizations and 3,500 startups)

Clinical Focus

Supporting innovation across oncology, cardiovascular, central nervous system, immunology, infectious diseases, respiratory, rare diseases, and neurodegenerative conditions.

Target Customers

Other companies and institutions, hospitals, device makers, drug manufacturers, researchers

Product Stage

Mature

Company Info

Business Model: B2B
Founded: 2019
Website: www.nvidia.com/en-us/

Disease Areas

Immunology and Infectious Diseases Respiratory Diseases Neurodegenerative Diseases Rare Diseases Cardiovascular Disease Central Nervous System Disorders Cancer & Oncology

Technologies

GPUsDeep LearningAccelerated ComputingNVIDIA ClaraBioNeMoHoloscanMONAIIsaac for HealthcareDigital Twin TechnologyPhysical AIGenomicsAI & Machine Learning

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of NVIDIA?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.